Media stories about Cardiome Pharma (NASDAQ:CRME) (TSE:COM) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cardiome Pharma earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.3213945313464 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of research analysts have commented on CRME shares. Canaccord Genuity set a $8.00 target price on Cardiome Pharma and gave the company a “buy” rating in a research note on Monday, August 21st. ValuEngine downgraded Cardiome Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. HC Wainwright set a $10.00 target price on Cardiome Pharma and gave the company a “buy” rating in a research note on Tuesday, August 22nd. Finally, Zacks Investment Research upgraded Cardiome Pharma from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $5.31.

Shares of Cardiome Pharma (NASDAQ CRME) traded down $0.03 during midday trading on Friday, reaching $1.43. The company’s stock had a trading volume of 56,900 shares, compared to its average volume of 111,105. The company has a current ratio of 5.52, a quick ratio of 4.71 and a debt-to-equity ratio of 1.67. Cardiome Pharma has a 1 year low of $1.29 and a 1 year high of $4.84.

Cardiome Pharma (NASDAQ:CRME) (TSE:COM) last issued its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). Cardiome Pharma had a negative net margin of 112.91% and a negative return on equity of 94.68%. The firm had revenue of $6.02 million during the quarter, compared to analysts’ expectations of $7.42 million. During the same quarter last year, the firm earned ($0.19) EPS. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. equities research analysts anticipate that Cardiome Pharma will post -0.84 EPS for the current fiscal year.

WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at

About Cardiome Pharma

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Insider Buying and Selling by Quarter for Cardiome Pharma (NASDAQ:CRME)

Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with's FREE daily email newsletter.